Phaseline

Companies › Ever Neuro Pharma

Ever Neuro Pharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 2, 1 Phase 4, 1 Phase 1; Neurology, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cerebrolysin
Neuroprotective peptide preparation from porcine brain
–Phase 2Cadasil; Disorder of Consciousness; Bell PalsyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05821075CerebrolysinPhase 1Bell PalsyNeurologyJan 2026
NCT05755997CerebrolysinPhase 2CadasilCardiovascularDec 2026
NCT04427241CerebrolysinPhase 4Disorder of ConsciousnessNeurologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

AMO Pharma Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.